Provided by Tiger Trade Technology Pte. Ltd.

OCUMENSION-B

6.850
+0.0801.18%
Volume:105.00K
Turnover:713.14K
Market Cap:5.58B
PE:-17.46
High:6.890
Open:6.890
Low:6.730
Close:6.770
52wk High:12.230
52wk Low:3.910
Shares:815.00M
HK Float Shares:815.00M
Volume Ratio:0.55
T/O Rate:0.01%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.392
ROE:-7.76%
ROA:-5.07%
PB:1.34
PE(LYR):-17.46
PS:9.04

Loading ...

FDA Expands Indication for Blood Disorder Drug, ACADIA Pharmaceuticals' Stock Soars

Deep News
·
Dec 24, 2025

Leadership Transition at Pharmaceutical Giant: The Real Story Behind the Change

Deep News
·
Dec 24, 2025

From the First Scandal to the Year-End Finale: Puli and Wuzhong Delisted, Bailing "Capped with ST"

Deep News
·
Dec 23, 2025

Investors Win Lawsuit Against Hainan Poly Pharm.Co.,Ltd. (300630)

Deep News
·
Dec 23, 2025

ASCLETIS-B (01672) Repurchases 200,000 Shares for HK$2.49 Million on December 22

Stock News
·
Dec 22, 2025

Ministry of Commerce Releases List of Companies Eligible for 2026 Licorice and Licorice Product Export Quota Bidding

Deep News
·
Dec 19, 2025

HK Stock Movement | MORIMATSU INTL (02155) Surges Over 8% as Pharma Equipment Cycle Recovers; Company is Global Leader in High-End Pressure Equipment

Stock News
·
Dec 19, 2025

ASCLETIS-B (01672) Repurchases 200,000 Shares for HK$2.6099 Million on December 16

Stock News
·
Dec 16, 2025

ASCLETIS-B (01672) Rebounds Nearly 3% as IL-17 Inhibitor ASC50 Achieves Positive Topline Results in US Phase I Study

Stock News
·
Dec 16, 2025

ASCLETIS-B (01672): Positive Topline Results from US Phase I Study of ASC50, a Potential Best-in-Class Oral Small Molecule IL-17 Inhibitor

Stock News
·
Dec 15, 2025

Hong Kong Stocks Open Lower: Hang Seng Index Down 1%, Pharmaceutical Sector Leads Declines with ASCLETIS-B (01672) Dropping Over 5%

Stock News
·
Dec 15, 2025

ASCLETIS-B (01672) Repurchases 300,000 Shares for Approximately HK$4.37 Million on December 12

Stock News
·
Dec 12, 2025

Danish Weight-Loss Drugmaker Zealand Unveils Ambitious 2030 Strategy

Deep News
·
Dec 11, 2025

Lupeng Pharma's IPO: Valuation Drops Despite R&D Milestones Amid Fierce Competition and Commercialization Challenges

Deep News
·
Dec 11, 2025

ASCLETIS-B (01672): First-in-Class FASN Inhibitor Denifanstat (ASC40) NDA for Acne Treatment Accepted by China NMPA

Stock News
·
Dec 10, 2025

Novartis AG (NVS.US) Bets $1.7 Billion on UK AI Biotech to Target Allergic Diseases

Stock News
·
Dec 09, 2025

Citi: Ascletis-B's ASC30 Phase IIa Data Further Demonstrates Best-in-Class Potential, Reiterates "Buy/High Risk" Rating

Deep News
·
Dec 09, 2025

Hong Kong Stocks Narrowly Fluctuate; ASCLETIS-B Surges Over 23% on Positive News

Deep News
·
Dec 09, 2025

Mirum Pharmaceuticals to Acquire Bluebird Therapeutics for Up to $820 Million

Deep News
·
Dec 08, 2025

Guizhou Sanli to Change Stock Abbreviation to "Sanli Pharmaceutical" from Dec 12

Deep News
·
Dec 08, 2025